FDA Approves Eli Lilly's Inluriyo for Advanced ER+ Breast Cancer
The FDA has approved Eli Lilly's Inluriyo (imlunestrant), an oral treatment for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, based on its ability to significantly improve progression-free survival in clinical trials, offering a new oral option for this patient group.